drugset
drugset / Trial / NCT04430348

PTX-35 in Patients With Advanced Solid Tumors

NCT04430348 ↗

Phase 1 Terminated 22 enrolled Pelican Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care

Timeline

Start
2020-06-04
Primary completion
2022-11-02
Completion
2023-06-15

Outcome

Outcome not reported

Stopped: “Absence of immunological response”

Drugs

EvaluationDrugModalityDoseRoute
Subject PTX-35 Monoclonal antibody 0.01 mg/kg Intravenous
Subject PTX-35 Monoclonal antibody 0.03 mg/kg Intravenous
Subject PTX-35 Monoclonal antibody 0.1 mg/kg Intravenous
Subject PTX-35 Monoclonal antibody 0.3 mg/kg Intravenous
Subject PTX-35 Monoclonal antibody 1 mg/kg Intravenous
Subject PTX-35 Monoclonal antibody 3 mg/kg Intravenous

Indications

neoplasm